Objective:
TFPI is a potent inhibitor of the tissue factor (TF)-induced extrinsic pathway of coagulation. Inhibition of TFPI with antibodies, aptamers, or peptide inhibitors improves hemostasis and may become an option for non-i.…
Introduction:
BAY 81-8973 is Bayer’s new full-length recombinant factor VIII (FVIII) product in development for the treatment of hemophilia A. BAY 81-8973 has no human- or animal- derived raw materials added to the cell culture,…
Objective:
Patient satisfaction with healthcare services enhances patient experience, improves outcomes, and is increasingly mandated by public and private payers. While many US Hemophilia Treatment Centers (HTC) periodically…
Introduction and Objectives:
In the phase 3 A-LONG and Kids A-LONG studies, subjects with severe hemophilia A receiving rFVIIIFc prophylaxis 1-2 times/week had low annualized bleeding rates (ABRs), with comparable pre-study and…
Introduction and Objectives:
In the phase 3 B-LONG and Kids B-LONG studies, subjects with severe hemophilia B receiving rFIXFc prophylaxis had low annualized bleeding rates (ABRs), with decreased weekly factor consumption and…